1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. PTC Therapeutics Acquires Censa Pharmaceuticals

M&A Deal Summary

PTC Therapeutics Acquires Censa Pharmaceuticals

On May 6, 2020, PTC Therapeutics acquired life science company Censa Pharmaceuticals for 10M USD

Acquisition Highlights
  • This is PTC Therapeutics’ 3rd transaction in the Life Science sector.
  • This is PTC Therapeutics’ 3rd largest (disclosed) transaction.
  • This is PTC Therapeutics’ 3rd transaction in the United States.
  • This is PTC Therapeutics’ 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2020-05-06
Target Censa Pharmaceuticals
Sector Life Science
Buyer(s) PTC Therapeutics
Deal Type Add-on Acquisition
Deal Value 10M USD

Target

Censa Pharmaceuticals

Wellesley, Massachusetts, United States
Censa Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth. Censa Pharmaceuticals is based in Wellesley, Massachusetts.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

PTC Therapeutics

South Plainfield, New Jersey, United States
Category Company
Founded 1998
Sector Life Science
Employees939
Revenue 807M USD (2024)
DESCRIPTION

PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. PTC Therapeutics was founded in 1998 and is based in South Plainfield, New Jersey.

DEAL STATS #
Overall 3 of 3
Sector: Life Science M&A 3 of 3
Type: Add-on Acquisition M&A Deals 2 of 2
State: Massachusetts M&A 2 of 2
Country: United States M&A 3 of 3
Year: 2020 M&A 1 of 1
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-07-19 Agilis Biotherapeutics

Cambridge, Massachusetts, United States

Agilis Biotherapeutics, Inc. is a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system (CNS). Agilis Biotherapeutics was founded in 2013 and is based in Cambridge, Massachusetts.

Buy $200M
Mergr

Solution for

Product

Company

Legal